Literature DB >> 25449517

Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension.

Guido Grassi1, Gino Seravalle2, Gianmaria Brambilla3, Claudio Pini4, Marina Alimento5, Rita Facchetti3, Domenico Spaziani6, Cesare Cuspidi7, Giuseppe Mancia2.   

Abstract

BACKGROUND: An increase in sympathetic drive to the heart and the peripheral circulation characterizes mild and severe essential hypertension. However, it remains unsettled whether sympathetic cardiovascular influences are potentiated in true resistant hypertension (RHT).
METHODS: In 32 RHT patients treated with 4.6 ± 0.3 drugs (mean ± SEM) and aged 58.6 ± 2.1 years, 35 non-resistant treated hypertensives (HT) and 19 normotensive controls (NT), all age-matched with RHT, we measured clinic, 24-hour ambulatory and beat-to-beat blood pressures (BP), heart rate (HR, EKG), muscle sympathetic nerve traffic (MSNA, microneurography) and spontaneous baroreflex MSNA-sensitivity.
RESULTS: BP values were markedly greater in RHT patients than in NT and HT (172.2 ± 1.7/100.7 ± 1.2 vs 132.1 ± 1.3/82.1 ± 0.9 and 135.5 ± 1.2/83.6 ± 0.9 mmHg, P < 0.01). This was paralleled by a significant and marked increase in MSNA (87.8 ± 2.0 vs 46.8 ± 2.6 and 59.3 ± 1.7 and bursts/100 heartbeats, P < 0.01). In multiple regression analysis the MSNA increase observed in RHT was significantly related to hemodynamic, hormonal and metabolic variables. It was also significantly related to plasma aldosterone values as well as spontaneous baroreflex MSNA-sensitivity, which were the variables that at the multivariate analysis were more closely related to the adrenergic activation of RHT after adjustment for confounders, including antihypertensive treatment (r(2)partial=0.04405 and r(2)partial=0.00878, P<0.05 for both).
CONCLUSIONS: These data represent the first evidence that RHT is a state of marked adrenergic overdrive, greater for magnitude than that detectable in HT. They also suggest that impaired baroreflex mechanisms, along with hemodynamic and neurohumoral factors, may be responsible for the phenomenon.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Baroreceptors; Blood pressure; Nervous system; Reflex; Resistant hypertension

Mesh:

Substances:

Year:  2014        PMID: 25449517     DOI: 10.1016/j.ijcard.2014.09.138

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  34 in total

Review 1.  Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications.

Authors:  Mario Habek
Journal:  Clin Auton Res       Date:  2019-04-08       Impact factor: 4.435

Review 2.  Electrical carotid sinus stimulation: chances and challenges in the management of treatment resistant arterial hypertension.

Authors:  Kristine Chobanyan-Jürgens; Jens Jordan
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 3.  Carotid baroreflex activation therapy for resistant hypertension.

Authors:  Ronald G Victor
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

4.  Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension.

Authors:  Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach
Journal:  Clin Res Cardiol       Date:  2019-04-06       Impact factor: 5.460

Review 5.  Carotid Baroreceptor Stimulation in Resistant Hypertension and Heart Failure.

Authors:  Gino Seravalle; Guido Grassi
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-27

Review 6.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 7.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 8.  Device-Based Approaches for the Treatment of Arterial Hypertension.

Authors:  Jens Jordan
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

9.  Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension.

Authors:  Christian Ott; Christoph Kopp; Anke Dahlmann; Axel Schmid; Peter Linz; Alexander Cavallaro; Matthias Hammon; Tilmann Ditting; Roland Veelken; Michael Uder; Jens Titze; Roland E Schmieder
Journal:  Clin Res Cardiol       Date:  2017-08-28       Impact factor: 5.460

10.  Coronary flow reserve in patients with resistant hypertension.

Authors:  Sebastian Völz; Sara Svedlund; Bert Andersson; Gan Li-Ming; Bengt Rundqvist
Journal:  Clin Res Cardiol       Date:  2016-10-17       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.